Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says

MT Newswires Live11-07

Natera (NTRA) reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its growth outlook in minimal residual disease testing, while its 2029 revenue target and CEO transition represent key developments for the company, RBC Capital Markets said in a note Friday.

The investment firm said Natera's dominant position in minimal residual disease monitoring provides opportunities in a market with a total addressable market of more than $15 billion.

RBC also highlighted the CEO transition, with Steve Chapman stepping down after nearly eight years and Solomon Moshkevich named as his successor. The investment firm said management's $6 billion revenue target for 2029 is consistent with its existing estimates and does not require overly ambitious assumptions.

It expects further growth from new coverage decisions and additional indications and noted that Signatera's average selling price increased to approximately $1,290 in Q3 from $1,271 in Q2.

The investment firm raised its operating expense assumptions for 2027 to reflect increased research and development spending, while slightly lowering gross margin estimates to account for new product launches.

RBC maintained its $460 price target on Natera, with an outperform rating.

The company's shares were down nearly 16% in Friday afternoon trading.

Price: 306.70, Change: -57.06, Percent Change: -15.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681891929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-07 03:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681891929","market":"us","top_or_hot":-1,"title":"Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Natera (NTRA) reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its growth outlook in minimal residual disease testing, while its 2029 revenue target and CEO transition represent key developments for the company, RBC Capital Markets said in a note Friday.</p><p>The investment firm said Natera's dominant position in minimal residual disease monitoring provides opportunities in a market with a total addressable market of more than $15 billion.</p><p>RBC also highlighted the CEO transition, with Steve Chapman stepping down after nearly eight years and Solomon Moshkevich named as his successor. The investment firm said management's $6 billion revenue target for 2029 is consistent with its existing estimates and does not require overly ambitious assumptions.</p><p>It expects further growth from new coverage decisions and additional indications and noted that Signatera's average selling price increased to approximately $1,290 in Q3 from $1,271 in Q2.</p><p>The investment firm raised its operating expense assumptions for 2027 to reflect increased research and development spending, while slightly lowering gross margin estimates to account for new product launches.</p><p>RBC maintained its $460 price target on Natera, with an outperform rating.</p><p>The company's shares were down nearly 16% in Friday afternoon trading.</p><p>Price: 306.70, Change: -57.06, Percent Change: -15.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-11-07 03:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Natera (NTRA) reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its growth outlook in minimal residual disease testing, while its 2029 revenue target and CEO transition represent key developments for the company, RBC Capital Markets said in a note Friday.</p><p>The investment firm said Natera's dominant position in minimal residual disease monitoring provides opportunities in a market with a total addressable market of more than $15 billion.</p><p>RBC also highlighted the CEO transition, with Steve Chapman stepping down after nearly eight years and Solomon Moshkevich named as his successor. The investment firm said management's $6 billion revenue target for 2029 is consistent with its existing estimates and does not require overly ambitious assumptions.</p><p>It expects further growth from new coverage decisions and additional indications and noted that Signatera's average selling price increased to approximately $1,290 in Q3 from $1,271 in Q2.</p><p>The investment firm raised its operating expense assumptions for 2027 to reflect increased research and development spending, while slightly lowering gross margin estimates to account for new product launches.</p><p>RBC maintained its $460 price target on Natera, with an outperform rating.</p><p>The company's shares were down nearly 16% in Friday afternoon trading.</p><p>Price: 306.70, Change: -57.06, Percent Change: -15.69</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2681891929","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2681891929","pubTimestamp":1793994428,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Natera  reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its growth outlook in minimal residual disease testing, while its 2029 revenue target and CEO transition represent key developments for the company, RBC Capital Markets said in a note Friday.The investment firm said Natera's dominant position in minimal residual disease monitoring provides opportunities in a market with a total addressable market of more than $15 billion.RBC also highlighted the CEO transition, with Steve Chapman stepping down after nearly eight years and Solomon Moshkevich named as his successor. The investment firm said management's $6 billion revenue target for 2029 is consistent with its existing estimates and does not require overly ambitious assumptions.It expects further growth from new coverage decisions and additional indications and noted that Signatera's average selling price increased to approximately $1,290 in Q3 from $1,271 in Q2.The investment firm raised its opera","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"加拿大皇家银行表示，Natera 第三季度业绩和 2029 年收入目标支持增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"Natera (NTRA) reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its growth outlook in minimal residual disease testing, while its 2029 revenue target and CEO transition represent key developments for the company, RBC Capital Markets said in a note Friday.The investment firm said Natera's dominant position in minimal residual disease monitoring provides opportunities in a market with a total addressable market of more than $15 billion.RBC also highlighted the CEO transition, with Steve Chapman stepping down after nearly eight years and Solomon Moshkevich named as his successor. The investment firm said management's $6 billion revenue target for 2029 is consistent with its existing estimates and does not require overly ambitious assumptions.It expects further growth from new coverage decisions and additional indications and noted that Signatera's average selling price increased to approximately $1,290 in Q3 from $1,271 in Q2.The investment firm raised its operating expense assumptions for 2027 to reflect increased research and development spending, while slightly lowering gross margin estimates to account for new product launches.RBC maintained its $460 price target on Natera, with an outperform rating.The company's shares were down nearly 16% in Friday afternoon trading.Price: 306.70, Change: -57.06, Percent Change: -15.69","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681891929","isCrawlerRequest":true}